<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1275" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1275/" /><meta name="ncbi_pagename" content="Spinocerebellar Ataxia Type 2 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Spinocerebellar Ataxia Type 2 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Spinocerebellar Ataxia Type 2" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/02/14" /><meta name="citation_author" content="Stefan M Pulst" /><meta name="citation_pmid" content="20301452" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1275/" /><meta name="citation_keywords" content="SCA2" /><meta name="citation_keywords" content="SCA 2" /><meta name="citation_keywords" content="SCA2" /><meta name="citation_keywords" content="Ataxin-2" /><meta name="citation_keywords" content="ATXN2" /><meta name="citation_keywords" content="Spinocerebellar Ataxia Type 2" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Spinocerebellar Ataxia Type 2" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Stefan M Pulst" /><meta name="DC.Date" content="2019/02/14" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1275/" /><meta name="description" content="Spinocerebellar ataxia type 2 (SCA2) is characterized by progressive cerebellar ataxia, including nystagmus, slow saccadic eye movements, and in some individuals, ophthalmoparesis or parkinsonism. Pyramidal findings are present; deep tendon reflexes are brisk early on and absent later in the course. Age of onset is typically in the fourth decade with a ten- to 15-year disease duration." /><meta name="og:title" content="Spinocerebellar Ataxia Type 2" /><meta name="og:type" content="book" /><meta name="og:description" content="Spinocerebellar ataxia type 2 (SCA2) is characterized by progressive cerebellar ataxia, including nystagmus, slow saccadic eye movements, and in some individuals, ophthalmoparesis or parkinsonism. Pyramidal findings are present; deep tendon reflexes are brisk early on and absent later in the course. Age of onset is typically in the fourth decade with a ten- to 15-year disease duration." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1275/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/sca2/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1275/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89ABD2E04034F1000000000AA60487.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1275_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1275_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sca1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sca3/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1275_"><span class="title" itemprop="name">Spinocerebellar Ataxia Type 2</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: SCA2</div><p class="contrib-group"><span itemprop="author">Stefan M Pulst</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1275_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1275_ai__"><div class="contrib half_rhythm"><span itemprop="author">Stefan M Pulst</span>, MD<div class="affiliation small">Department of Neurology<br />University of Utah<br />Salt Lake City, Utah<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.hatu.csh@tslup.nafets" class="oemail">ude.hatu.csh@tslup.nafets</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">October 23, 1998</span>; Last Update: <span itemprop="dateModified">February 14, 2019</span>.</p><p><em>Estimated reading time: 21 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="sca2.Summary" itemprop="description"><h2 id="_sca2_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Spinocerebellar ataxia type 2 (SCA2) is characterized by progressive cerebellar ataxia, including nystagmus, slow saccadic eye movements, and in some individuals, ophthalmoparesis or parkinsonism. Pyramidal findings are present; deep tendon reflexes are brisk early on and absent later in the course. Age of onset is typically in the fourth decade with a ten- to 15-year disease duration.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of SCA2 rests on the use of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to detect an abnormal CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion in <i>ATXN2</i>. Affected individuals have alleles with 33 or more CAG trinucleotide repeats.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Management is supportive. Affected individuals should maintain activity. Canes and walkers help prevent falls; grab bars, raised toilet seats, and ramps to accommodate motorized chairs may be necessary. Speech therapy and communication devices such as writing pads and computer-based devices may benefit those with dysarthria. Weighted eating utensils and dressing hooks help maintain a sense of independence. When dysphagia becomes troublesome, video swallowing studies can identify the consistency of food least likely to trigger aspiration.</p><p><i>Prevention of secondary complications:</i> Vitamin supplements are recommended; weight control helps minimize difficulties with ambulation and mobility.</p><p><i>Surveillance:</i> Annual examination by a physician experienced in movement disorders and ataxia.</p><p><i>Agents/circumstances to avoid:</i> Alcohol and medications known to affect cerebellar function.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>SCA2 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Offspring of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual have a 50% chance of inheriting the causative CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion. The repeat may expand significantly, especially when transmitted by the father. Prenatal testing for pregnancies at increased risk is possible if the diagnosis has been established by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in an affected family member.</p></div></div><div id="sca2.Diagnosis"><h2 id="_sca2_Diagnosis_">Diagnosis</h2><div id="sca2.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Spinocerebellar ataxia type 2 (SCA2) <b>should be suspected</b> in individuals with the following:</p><ul><li class="half_rhythm"><div>Slowly progressive ataxia and dysarthria</div></li><li class="half_rhythm"><div>Nystagmus and slow saccadic eye movements</div></li><li class="half_rhythm"><div>Family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance</div></li></ul></div><div id="sca2.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of SCA2 <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ATXN2</i> (see <a class="figpopup" href="/books/NBK1275/table/sca2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figsca2Tmoleculargenetictestingusedin" rid-ob="figobsca2Tmoleculargenetictestingusedin">Table 1</a>). The clinical features of SCA2 do not allow diagnosis with certainty; thus, diagnosis depends on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p><b>Allele sizes</b></p><ul><li class="half_rhythm"><div><b>Alleles not causing SCA2.</b> Alleles with 31 or fewer CAG repeats</div></li><li class="half_rhythm"><div><b>Alleles of uncertain clinical significance.</b> Alleles with 32 repeats are uncommon; correlation with clinical findings and family history may be helpful.</div></li><li class="half_rhythm"><div><b>Alleles predisposed to meiotic instability (longer normal alleles)</b> have a CAG length-dependent increased instability [<a class="bk_pop" href="#sca2.REF.almaguermederos.2018.346">Almaguer-Mederos et al 2018</a>]. Precise risk estimates based on large numbers of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals from different ethnic groups are not available. In a small number of observations, presence of an uninterrupted (pure CAG) repeat structure increases risk of expansion and conversely, CAA interruptions appear to stabilize the repeat in transmissions.</div></li><li class="half_rhythm"><div><b>Amyotrophic lateral sclerosis-risk alleles.</b> Alleles with 30, 31, or 32 repeats [<a class="bk_pop" href="#sca2.REF.neuenschwander.2014.1529">Neuenschwander et al 2014</a>]</div></li><li class="half_rhythm"><div><b>Recessive SCA2-causing alleles.</b> Homozygous 31/31 repeat alleles [<a class="bk_pop" href="#sca2.REF.tojima.2018.e283">Tojima et al 2018</a>]</div></li><li class="half_rhythm"><div><b>Dominant SCA2-causing alleles.</b> Alleles with 33 or more CAG repeats (see Note) [<a class="bk_pop" href="#sca2.REF.pulst.1996.269">Pulst et al 1996</a>, <a class="bk_pop" href="#sca2.REF.charles.2007.1970">Charles et al 2007</a>]. Persons who have an SCA2-causing <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> are considered at risk of developing SCA2 in their lifetime. SCA2-causing alleles are further classified as follows:</div><ul><li class="half_rhythm"><div><b>Reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> SCA2-causing alleles.</b> 33-34 CAG trinucleotide repeats. An individual with an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in this range is at risk for SCA2 but may not develop symptoms. Alleles of 33 CAG repeats are considered "late onset" (age &#x0003e;50 years). An older asymptomatic individual with 34 CAG repeats has been reported [<a class="bk_pop" href="#sca2.REF.riess.1997.59">Riess et al 1997</a>].</div></li><li class="half_rhythm"><div><b>Full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> SCA2-causing alleles.</b> The most common disease-causing alleles have 37 to 39 repeats. Extreme CAG repeat expansion (&#x0003e;200) has been reported [<a class="bk_pop" href="#sca2.REF.babovicvuksanovic.1998.383">Babovic-Vuksanovic et al 1998</a>] (see <a href="#sca2.Anticipation">Anticipation</a>).</div></li></ul></li></ul><p>Note: Interruption of a CAG expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> by a CAA repeat does not mitigate the pathogenicity of the repeat size because both CAG and CAA code for glutamine [<a class="bk_pop" href="#sca2.REF.costanziporrini.2000.491">Costanzi-Porrini et al 2000</a>]; however, the interruption may enhance the meiotic stability of the repeat [<a class="bk_pop" href="#sca2.REF.choudhry.2001.2437">Choudhry et al 2001</a>]. Conversely, the lack of CAA interruption in some expanded alleles may increase the instability of the expansion and therefore increase the risk of transmission of a larger expansion to offspring, who may become symptomatic.</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Targeted analysis for a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>ATXN2</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> with &#x0003e;31 CAG repeats should be performed first.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ATXN2</i> CAG-repeat analysis and other genes of interest (see <a href="#sca2.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="sca2.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in SCA2</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1275/table/sca2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca2.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sca2.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_sca2.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_sca2.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_sca2.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATXN2</i></td><td headers="hd_h_sca2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>3</sup></td><td headers="hd_h_sca2.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="sca2.TF.1.1"><p class="no_margin">See <a href="/books/NBK1275/#sca2.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="sca2.TF.1.2"><p class="no_margin">See <a href="#sca2.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="sca2.TF.1.3"><p class="no_margin">Detects abnormal number of CAG trinucleotide repeats. <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> amplification detects smaller CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansions up to ~100 repeats. Southern blotting is required to detect highly expanded CAG trinucleotide repeat expansions (&#x0003e;100 repeats) and may be indicated in symptomatic infants and children [<a class="bk_pop" href="#sca2.REF.mao.2002.338">Mao et al 2002</a>].</p></div></dd></dl></div></div></div><p>Note: Testing individuals with a positive family history of ataxia has a much higher yield than testing individuals with ataxia without an obvious family history.</p><ul><li class="half_rhythm"><div>In the series reported by <a class="bk_pop" href="#sca2.REF.riess.1997.59">Riess et al [1997]</a> only two of 842 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals without a family history of ataxia were <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>ATXN2</i> expansion in the pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> size range.</div></li><li class="half_rhythm"><div>In the series reported by <a class="bk_pop" href="#sca2.REF.cancel.1997.709">Cancel et al [1997]</a> only two of 90 individuals with olivopontocerebellar atrophy without a known family history were <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>ATXN2</i> expansion in the pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> size range.</div></li></ul></div></div><div id="sca2.Clinical_Characteristics"><h2 id="_sca2_Clinical_Characteristics_">Clinical Characteristics</h2><div id="sca2.Clinical_Description"><h3>Clinical Description</h3><p>Spinocerebellar ataxia type 2 (SCA2) is characterized by slowly progressive ataxia and dysarthria associated with the ocular findings of nystagmus, slow saccadic eye movements, and in some individuals, ophthalmoparesis. Tendon reflexes are brisk during the first years of life, but absent later. Mean age of onset is typically in the fourth decade with a ten- to 15-year disease duration. The disease is more rapidly progressive when onset occurs before age 20 years.</p><p>In the original study from Cuba, the earliest symptoms included gait ataxia often accompanied by leg cramps [<a class="bk_pop" href="#sca2.REF.orozco_diaz.1990.1369">Orozco Diaz et al 1990</a>]. More than 50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals developed a kinetic or postural tremor, decreased muscle tone, decreased tendon reflexes, and abnormal eye movements with slowed saccades progressing to supranuclear ophthalmoplegia. Detailed analyses of the eye movement abnormalities have been reported [<a class="bk_pop" href="#sca2.REF.engel.2004.778">Engel et al 2004</a>, <a class="bk_pop" href="#sca2.REF.vel_zquezp_rez.2004.444">Vel&#x000e1;zquez-P&#x000e9;rez et al 2004</a>].</p><p>In individuals with molecularly confirmed <i>ATXN2</i>, <a class="bk_pop" href="#sca2.REF.geschwind.1997b.842">Geschwind et al [1997b]</a> found almost universal presence of cerebellar ataxia and slow saccadic eye movements in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, as well as a relatively high incidence of dystonia or chorea (38%) and dementia (37%). Mild, primarily cerebellar symptoms appeared to segregate in some families, whereas others had an early onset with dementia and chorea. <a class="bk_pop" href="#sca2.REF.luo.2017.615">Luo et al [2017]</a> described the initial manifestations in SCA2 and other ataxias.</p><p>Similar findings were also reported by <a class="bk_pop" href="#sca2.REF.cancel.1997.709">Cancel et al [1997]</a> in a series of 111 individuals from 32 families of diverse origins. Slow eye movements were seen in 56%, fasciculations in 25%, and dystonia in 9%. The authors also correlated these findings with disease duration and increasing CAG repeat length.</p><p>An SCA2 <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> that includes L-dopa-responsive parkinsonism has been reported [<a class="bk_pop" href="#sca2.REF.furtado.2002.1625">Furtado et al 2002</a>, <a class="bk_pop" href="#sca2.REF.payami.2003.425">Payami et al 2003</a>, <a class="bk_pop" href="#sca2.REF.charles.2007.1970">Charles et al 2007</a>]. In one Alberta family, the phenotype was consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> Parkinson disease, with PET scan showing reduced striatal fluorodopa uptake and normal raclopride binding in two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> members [<a class="bk_pop" href="#sca2.REF.furtado.2002.1625">Furtado et al 2002</a>]. <a class="bk_pop" href="#sca2.REF.charles.2007.1970">Charles et al [2007]</a> proposed that an interrupted repeat structure may lead to differential binding with RNA-binding proteins and thus result in a parkinsonian rather than a cerebellar phenotype.</p><p><b>Neuropathology.</b> Seven postmortem examinations have been reported in the Holguin population of Cuba [<a class="bk_pop" href="#sca2.REF.orozco.1989.37">Orozco et al 1989</a>]. A marked reduction in the number of cerebellar Purkinje cells was observed. In silver preparations, Purkinje cell dendrites had poor arborization and torpedo-like formation of their axons as they passed through the granular layer. Parallel fibers were scant and granule cells were decreased in number, whereas Golgi and basket cells were well preserved, as were neurons in the dentate and other cerebellar nuclei. In the brain stem, marked neuronal loss in the inferior olive and pontocerebellar nuclei was observed. Six of seven brains also had marked loss in the substantia nigra. In five spinal cords that were available for analysis, marked demyelination was present in the posterior columns and to a lesser degree in the spinocerebellar tracts. Motor neurons and neurons in Clarke's column were reduced in size and number. In the lumbar and sacral segments, anterior and posterior roots were partially demyelinated. Degeneration in the thalamus and reticulotegmental nucleus of the pons has also been reported [<a class="bk_pop" href="#sca2.REF.r_b.2003.2257">R&#x000fc;b et al 2003</a>, <a class="bk_pop" href="#sca2.REF.r_b.2004.1258">R&#x000fc;b et al 2004</a>, <a class="bk_pop" href="#sca2.REF.r_b.2005.127">R&#x000fc;b et al 2005</a>].</p><p>In addition, <a class="bk_pop" href="#sca2.REF.orozco.1989.37">Orozco et al [1989]</a> noted severe gyral atrophy, most prominent in the frontotemporal lobes. The cerebral cortex was thinned, but without neuronal rarefaction. The cerebral white matter was atrophic and gliotic. Degeneration in the pallidonigroluysian system mainly involved the substantia nigra. One brain showed patchy loss in parts of the third-nerve nuclei. <a class="bk_pop" href="#sca2.REF.adams.1997.1163">Adams et al [1997]</a> reported similar findings in one individual.</p><p><a class="bk_pop" href="#sca2.REF.seidel.2017.345">Seidel et al [2017]</a> studied the distribution of polyQ aggregates in brain stem sections of individuals with SCA2 and found that cytoplasmic aggregates correlated with disease severity.</p><p>An <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with white matter pathology has been described [<a class="bk_pop" href="#sca2.REF.armstrong.2005.247">Armstrong et al 2005</a>].</p><p>Nerve biopsy has shown moderate loss of large myelinated fibers [<a class="bk_pop" href="#sca2.REF.filla.1995.793">Filla et al 1995</a>].</p></div><div id="sca2.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b>Probands.</b> In general, a clear inverse correlation exists between age of onset and CAG repeat length. However, repeat length cannot predict age of onset or disease severity in an individual. About 50% of age-of-onset variance is not explained by CAG repeat length [<a class="bk_pop" href="#sca2.REF.figueroa.2017.e155">Figueroa et al 2017</a>].</p><ul><li class="half_rhythm"><div>The widest range of age of onset is observed among individuals with fewer than 40 CAG repeats. Some individuals with alleles of 33 and 34 repeats have had onset after age 60 years. In one study, the presence of 37 repeats was associated with ages of onset ranging from 20 to 60 years [<a class="bk_pop" href="#sca2.REF.pulst.1996.269">Pulst et al 1996</a>].</div></li><li class="half_rhythm"><div>For larger repeat sizes, the variability in age of onset is less; repeat sizes greater than 45 are almost always associated with disease onset before age 20 years [<a class="bk_pop" href="#sca2.REF.imbert.1996.285">Imbert et al 1996</a>, <a class="bk_pop" href="#sca2.REF.pulst.1996.269">Pulst et al 1996</a>, <a class="bk_pop" href="#sca2.REF.sanpei.1996.277">Sanpei et al 1996</a>, <a class="bk_pop" href="#sca2.REF.cancel.1997.709">Cancel et al 1997</a>, <a class="bk_pop" href="#sca2.REF.geschwind.1997b.842">Geschwind et al 1997b</a>, <a class="bk_pop" href="#sca2.REF.riess.1997.59">Riess et al 1997</a>, <a class="bk_pop" href="#sca2.REF.moretti.2004.392">Moretti et al 2004</a>].</div></li></ul><p>Homozygosity for expanded <i>ATXN2</i> alleles (2 alleles in the pathogenic range) does not appear to influence age of onset [<a class="bk_pop" href="#sca2.REF.sanpei.1996.277">Sanpei et al 1996</a>].</p><p><b>At-risk individuals.</b> The age of onset, severity, specific symptoms, and progression of the disease are variable and cannot be predicted by the family history or by molecular genetic (DNA) testing.</p></div><div id="sca2.Penetrance"><h3>Penetrance</h3><p>See <a href="#sca2.Establishing_the_Diagnosis">Establishing the Diagnosis</a>, <b>Allele sizes</b> and <a href="#sca2.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div><div id="sca2.Anticipation"><h3>Anticipation</h3><p>Anticipation (i.e., an increase in the severity of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and earlier age of onset in later generations) has been observed in SCA2. The tendency of the <i>ATXN2</i> CAG repeat to expand as it is transmitted provides a biologic explanation for the earlier age of onset in subsequent generations.</p><p>Paternal transmission of alleles with full <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> or reduced penetrance is most likely to demonstrate meiotic instability and result in <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a>, although large expansions can also be seen in maternally inherited alleles [<a class="bk_pop" href="#sca2.REF.figueroa.2017.e155">Figueroa et al 2017</a>]. In one case report, a man who had 43 repeats and onset of symptoms at age 22 years had an infant with apnea, hypotonia, and dysphagia and an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> of 202 CAG repeats [<a class="bk_pop" href="#sca2.REF.babovicvuksanovic.1998.383">Babovic-Vuksanovic et al 1998</a>]. <a class="bk_pop" href="#sca2.REF.mao.2002.338">Mao et al [2002]</a> identified large expansions in four individuals using a <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> assay.</p></div><div id="sca2.Nomenclature"><h3>Nomenclature</h3><p>Terms used in the past for SCA2 and other hereditary ataxias include Marie's ataxia, OPCA, and <i>forme fruste</i> of Friedreich ataxia. These terms are no longer in use.</p></div><div id="sca2.Prevalence"><h3>Prevalence</h3><p><a class="bk_pop" href="#sca2.REF.geschwind.1997b.842">Geschwind et al [1997b]</a> found that in an ethnically varied population in the University of California Los Angeles ataxia clinic, SCA2 accounted for 13% of the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> cerebellar ataxias (ADCAs) compared with 6% for <a href="/books/n/gene/sca1/">SCA1</a> and 23% for <a href="/books/n/gene/sca3/">SCA3</a>. A similar percentage (15%) was reported by <a class="bk_pop" href="#sca2.REF.cancel.1997.709">Cancel et al [1997]</a> in 184 families from an ethnically and geographically diverse population.</p><p>In the Baylor College of Medicine ataxia clinic, SCA2 was the most common ADCA (18%) [<a class="bk_pop" href="#sca2.REF.lorenzetti.1997.1009">Lorenzetti et al 1997</a>]. <a class="bk_pop" href="#sca2.REF.moseley.1998.1666">Moseley et al [1998]</a> reported that SCA2 was common in individuals presenting to an ataxia clinic at an academic medical center, representing 15% of persons from families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance and 2% of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) [<a class="bk_pop" href="#sca2.REF.moseley.1998.1666">Moseley et al 1998</a>].</p><p>In a large series from several ataxia clinics in Germany, SCA2 represented 14% of ADCA pedigrees [<a class="bk_pop" href="#sca2.REF.riess.1997.59">Riess et al 1997</a>].</p><p>SCA2 is the most common type of ADCA in Korea [<a class="bk_pop" href="#sca2.REF.lee.2003.858">Lee et al 2003</a>]. (See also <a href="/books/n/gene/ataxias/">Hereditary Ataxia Overview</a>.)</p></div></div><div id="sca2.Genetically_Related_Allelic_Disorde"><h2 id="_sca2_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>In addition to ataxia, L-dopa-responsive parkinsonism with or without ataxia has been reported in individuals and families with the <i>ATXN2</i> CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion.</p></div><div id="sca2.Differential_Diagnosis"><h2 id="_sca2_Differential_Diagnosis_">Differential Diagnosis</h2><p>It is difficult and often impossible to distinguish spinocerebellar ataxia type 2 (SCA2) from the other hereditary ataxias (see <a href="/books/n/gene/ataxias/">Hereditary Ataxia Overview</a>). The differential diagnosis should also include <a href="/books/n/gene/parkinson-overview/">Parkinson disease</a> and acquired causes of cerebellar ataxia.</p><p>SCA2-related <i>ATXN2</i> pathogenic variants should be in the differential diagnosis of adult-onset <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> progressive ataxia, multiple system atrophy (MSA, Shy-Drager syndrome; OMIM <a href="http://omim.org/entry/146500" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">146500</a>), L-dopa-responsive parkinsonism, atypical <a href="/books/n/gene/friedreich/">Friedreich ataxia</a> [<a class="bk_pop" href="#sca2.REF.abele.2002.961">Abele et al 2002</a>], and <a href="/books/n/gene/als-overview/">amyotrophic lateral sclerosis</a> [<a class="bk_pop" href="#sca2.REF.neuenschwander.2014.1529">Neuenschwander et al 2014</a>].</p><div id="sca2.T.proportion_of_individuals_with_sc" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Proportion of Individuals with SCA2 Manifesting Phenotypic Features Compared with Individuals with SCA1, SCA3, and SCA6</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1275/table/sca2.T.proportion_of_individuals_with_sc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca2.T.proportion_of_individuals_with_sc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotypic Feature</th><th id="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SCA2</th><th id="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SCA1</th><th id="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SCA3</th><th id="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SCA6</th></tr></thead><tbody><tr><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cerebellar dysfunction</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr><tr><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reduced saccadic velocity</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">71%-92%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%-6%</td></tr><tr><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myoclonus</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%-40%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td></tr><tr><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystonia or chorea</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%-38%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%-25%</td></tr><tr><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pyramidal involvement</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">29%-31%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">33%-44%</td></tr><tr><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Peripheral neuropathy</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">44%-94%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16%-44%</td></tr><tr><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Intellectual impairment</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">31%-37%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%</td><td headers="hd_h_sca2.T.proportion_of_individuals_with_sc_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Percentages modified from <a class="bk_pop" href="#sca2.REF.geschwind.1997a.1247">Geschwind et al [1997a]</a>, <a class="bk_pop" href="#sca2.REF.geschwind.1997b.842">Geschwind et al [1997b]</a>, <a class="bk_pop" href="#sca2.REF.sch_ls.1997a.924">Sch&#x000f6;ls et al [1997a]</a>, and <a class="bk_pop" href="#sca2.REF.sch_ls.1997b.1073">Sch&#x000f6;ls et al [1997b]</a></p></div></dd></dl></div></div></div></div><div id="sca2.Management"><h2 id="_sca2_Management_">Management</h2><div id="sca2.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with spinocerebellar ataxia type 2 (SCA2), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Neurologic examination</div></li><li class="half_rhythm"><div>Ophthalmologic examination</div></li><li class="half_rhythm"><div>Baseline assessment of cognition</div></li><li class="half_rhythm"><div>Neuroimaging</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="sca2.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management of individuals remains supportive as no known therapy to delay or halt the progression of the disease exists.</p><p>Although neither exercise nor physical therapy has been shown to stem the progression of incoordination or muscle weakness, individuals should maintain activity.</p><p>Canes and walkers help prevent falls.</p><p>Modification of the home with such conveniences as grab bars, raised toilet seats, and ramps to accommodate motorized chairs may be necessary.</p><p>Speech therapy and communication devices such as writing pads and computer-based devices may benefit those with dysarthria.</p><p>Weighted eating utensils and dressing hooks help maintain a sense of independence.</p><p>When dysphagia becomes troublesome, video esophagrams can identify the consistency of food least likely to trigger aspiration.</p><p>Improvement of severe tremor with thalamic stimulation has been reported in one individual [<a class="bk_pop" href="#sca2.REF.pirker.2003.222">Pirker et al 2003</a>]. Another individual showed improvement with stimulation of the subthalamic nucleus [<a class="bk_pop" href="#sca2.REF.freund.2007.732">Freund et al 2007</a>].</p><p>The American Academy of Neurology has developed guidelines for the treatment of motor dysfunction in patients with ataxia [<a class="bk_pop" href="#sca2.REF.zesiewicz.2018.464">Zesiewicz et al 2018</a>].</p></div><div id="sca2.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>No dietary factor has been shown to curtail symptoms; however, vitamin supplements are recommended, particularly if caloric intake is reduced.</p><p>Weight control is important because obesity can exacerbate difficulties with ambulation and mobility.</p></div><div id="sca2.Surveillance"><h3>Surveillance</h3><p>Affected individuals should be examined at least annually by a physician experienced in movement disorders and ataxia.</p></div><div id="sca2.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Alcohol and medications known to affect cerebellar function should be avoided.</p></div><div id="sca2.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#sca2.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="sca2.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="sca2.Other"><h3>Other</h3><p>Tremor-controlling drugs do not work well for cerebellar tremors.</p></div></div><div id="sca2.Genetic_Counseling"><h2 id="_sca2_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="sca2.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Spinocerebellar ataxia type 2 (SCA2) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="sca2.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with SCA2 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with SCA2 may have the disorder as the result of an expansion of a <a class="def" href="/books/n/gene/glossary/def-item/reduced-penetrance-allele/">reduced-penetrance allele</a> or a longer normal allele inherited from an unaffected parent.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of apparently asymptomatic parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> include physical examination and consideration of <i>ATXN2</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li><li class="half_rhythm"><div>Although most individuals diagnosed with SCA2 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent or a parent with a longer normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of a proband depends on the genetic status of the parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>ATXN2</i> CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion, the risk to the sibs is 50%. However, age of onset, severity, specific symptoms, and progression of the disease are variable and cannot be predicted by the family history or the size of the inherited expansion.</div></li><li class="half_rhythm"><div>If an expanded <i>ATXN2</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> (no instances of germline mosaicism have been reported, although it remains a possibility).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with SCA2 has a 50% chance of inheriting an expanded <i>ATXN2</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>Further <i>ATXN2</i> CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion may occur when the expanded <i>ATXN2</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is transmitted to offspring. This results in <a href="#sca2.Anticipation">anticipation</a> (an earlier age of onset and more severe disease manifestations in offspring).</div></li><li class="half_rhythm"><div>Large expansions are almost exclusively observed when the repeat is passed through the paternal <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> [<a class="bk_pop" href="#sca2.REF.geschwind.1997b.842">Geschwind et al 1997b</a>, <a class="bk_pop" href="#sca2.REF.riess.1997.59">Riess et al 1997</a>] (see <a href="#sca2.Anticipation">Anticipation</a>). Nonetheless, the age of onset, severity, specific symptoms, and progression of the disease are variable and cannot be predicted by the family history or the size of the expansion.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the expanded <i>ATXN2</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, his or her family members may be at risk.</p></div><div id="sca2.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>At-risk individuals.</b> The age of onset, severity, specific symptoms, and progression of the disease are variable and cannot be predicted by the family history or results of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p><b>Predictive testing (i.e., testing of asymptomatic at-risk individuals)</b></p><ul><li class="half_rhythm"><div>Predictive testing for at-risk relatives is possible once <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has identified an <i>ATXN2</i> CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member.</div></li><li class="half_rhythm"><div>This testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals.</div></li><li class="half_rhythm"><div>Potential consequences of such testing (including but not limited to socioeconomic changes and the need for long-term follow up and evaluation arrangements for individuals with a positive test result) as well as the capabilities and limitations of predictive testing should be discussed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> prior to testing.</div></li></ul><p><b>Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals age &#x0003c;18 years)</b></p><ul><li class="half_rhythm"><div>For asymptomatic minors at risk for adult-onset conditions for which early treatment would have no beneficial effect on disease morbidity and mortality, predictive genetic testing is considered inappropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</div></li><li class="half_rhythm"><div>For more information, see the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</div></li></ul><p>In a family with an established diagnosis of SCA2, it is appropriate to consider testing of symptomatic individuals regardless of age.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="sca2.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once an <i>ATXN2</i> CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> expansion has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for SCA2 are possible.</p><p>Note: Prenatal testing must take into account the possibility of a highly expanded <i>ATXN2</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#sca2.REF.babovicvuksanovic.1998.383">Babovic-Vuksanovic et al 1998</a>].</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="sca2.Resources"><h2 id="_sca2_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22234/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Spinocerebellar ataxia</a></div></li><li class="half_rhythm"><div><b>Spinocerebellar Ataxia: Making an Informed Choice about Genetic Testing</b></div><div><i>Booklet providing information about Spinocerebellar Ataxia</i></div><div><a href="http://depts.washington.edu/neurolog/images/neurogenetics/ataxia.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">depts.washington.edu/neurolog/images/neurogenetics/ataxia.pdf</a></div></li><li class="half_rhythm"><div><b>Ataxia UK</b></div><div>Lincoln House</div><div>1-3 Brixton Road</div><div>London SW9 6DE</div><div>United Kingdom</div><div><b>Phone:</b> 0845 644 0606 (helpline); 020 7582 1444 (office); +44 (0) 20 7582 1444 (from abroad)</div><div><b>Email:</b> helpline@ataxia.org.uk; office@ataxia.org.uk</div><div><a href="http://www.ataxia.org.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org.uk</a></div></li><li class="half_rhythm"><div><b>euro-ATAXIA (European Federation of Hereditary Ataxias)</b></div><div>Ataxia UK</div><div>Lincoln House, Kennington Park, 1-3 Brixton Road</div><div>London SW9 6DE</div><div>United Kingdom</div><div><b>Phone:</b> +44 (0) 207 582 1444</div><div><b>Email:</b> smillman@ataxia.org.uk</div><div><a href="https://www.euroataxia.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.euroataxia.org</a></div></li><li class="half_rhythm"><div><b>National Ataxia Foundation</b></div><div>2600 Fernbrook Lane</div><div>Suite 119</div><div>Minneapolis MN 55447</div><div><b>Phone:</b> 763-553-0020</div><div><b>Email:</b> naf@ataxia.org</div><div><a href="http://www.ataxia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org</a></div></li><li class="half_rhythm"><div><b>Spanish Ataxia Federation (FEDAES)</b></div><div>Spain</div><div><b>Phone:</b> 34 983 278 029; 34 985 097 152; 34 634 597 503</div><div><b>Email:</b> sede.valladolid@fedaes.org; sede.gijon@fedaes.org; sede.bilbao@fedaes.org</div><div><a href="http://www.fedaes.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fedaes.org</a></div></li><li class="half_rhythm"><div><b>CoRDS Registry</b></div><div>Sanford Research</div><div>2301 East 60th Street North</div><div>Sioux Falls SD 57104</div><div><b>Phone:</b> 605-312-6423</div><div><b>Email:</b> sanfordresearch@sanfordhealth.org</div><div><a href="http://www.sanfordresearch.org/SpecialPrograms/cords/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CoRDS Registry</a></div></li></ul></div><div id="sca2.Molecular_Genetics"><h2 id="_sca2_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="sca2.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Spinocerebellar Ataxia Type 2: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1275/table/sca2.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca2.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_sca2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_sca2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_sca2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_sca2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_sca2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_sca2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_sca2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6311" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ATXN2</i></a></td><td headers="hd_b_sca2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6311" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12q24<wbr style="display:inline-block"></wbr>​.12</a></td><td headers="hd_b_sca2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q99700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ataxin-2</a></td><td headers="hd_b_sca2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://alsod.iop.kcl.ac.uk/Als/Overview/gene.aspx?gene_id=ATXN2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">alsod/ATXN2 genetic mutations</a><br /><a href="http://databases.lovd.nl/shared/genes/ATXN2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATXN2 database</a></td><td headers="hd_b_sca2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ATXN2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATXN2</a></td><td headers="hd_b_sca2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ATXN2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATXN2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="sca2.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="sca2.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Spinocerebellar Ataxia Type 2 (<a href="/omim/183090,601517" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1275/table/sca2.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca2.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/183090" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">183090</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPINOCEREBELLAR ATAXIA 2; SCA2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601517" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601517</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ATAXIN 2; ATXN2</td></tr></tbody></table></div></div><p><b>Benign variants.</b> Normal alleles have 31 or fewer CAG repeats. The two normal alleles, which account for more than 95% of alleles in most studies, have 22 and 23 CAG repeats [<a class="bk_pop" href="#sca2.REF.pulst.1996.269">Pulst et al 1996</a>, <a class="bk_pop" href="#sca2.REF.sanpei.1996.277">Sanpei et al 1996</a>, <a class="bk_pop" href="#sca2.REF.riess.1997.59">Riess et al 1997</a>].</p><p>Normal alleles typically show one or two CAA <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> interruptions. Because the CAA codon also encodes glutamine, these interruptions do not interrupt the glutamine tract at the protein level. The 5' sequence of the <i>ATXN2</i> <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> is extremely GC rich and two potential ATG initiation codons can be identified. The most 5' ATG is located 78 bp downstream of an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> stop codon. Use of this translation initiation site predicts a protein of 140.1 kd. The second ATG, which has a better Kozak consensus sequence, is located just 5' to the CAG repeat region and would result in a protein with a relative molecular weight of 125 kd.</p><p><b>Allele of uncertain clinical significance.</b> A 32-CAG repeat is an uncommon <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and information is insufficient to classify it as normal or pathogenic.</p><p><b>Risk alleles.</b> Amyotrophic lateral sclerosis risk alleles have 30, 31, or 32 repeats.</p><p><b>Alleles predisposed to meiotic instability (longer normal alleles)</b> have a CAG length-dependent increased instability [<a class="bk_pop" href="#sca2.REF.almaguermederos.2018.346">Almaguer-Mederos et al 2018</a>]. Precise risk estimates based on large numbers of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals from different ethnic groups are not available. In a small number of observations, presence of an uninterrupted (pure CAG) repeat structure increases risk of expansion and conversely, CAA interruptions appear to stabilize the repeat in transmissions.</p><p><b>Pathogenic variants.</b> Disease alleles have 33 or more CAG repeats [<a class="bk_pop" href="#sca2.REF.pulst.2005.2297">Pulst et al 2005</a>].</p><ul><li class="half_rhythm"><div><b>Reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> SCA2-causing alleles.</b> 33-34 CAG trinucleotide repeats. An individual with an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in this range is at risk for SCA2 but may not develop symptoms or only very late in life.</div></li><li class="half_rhythm"><div><b>Full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> SCA2-causing alleles.</b> More than 34 CAG trinucleotide repeats. Alleles of this size are associated with development of SCA2 with increased certainty assuming a normal life span. The most common disease-causing alleles have 37 to 39 repeats. Extreme CAG repeat expansion (&#x0003e;200) has been reported [<a class="bk_pop" href="#sca2.REF.babovicvuksanovic.1998.383">Babovic-Vuksanovic et al 1998</a>] (see <a href="#sca2.Anticipation">Anticipation</a>).</div></li></ul><p>Note: Interruption of a CAG expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> by a CAA repeat does not mitigate the pathogenicity of the repeat size because both CAG and CAA code for glutamine [<a class="bk_pop" href="#sca2.REF.costanziporrini.2000.491">Costanzi-Porrini et al 2000</a>]; however, the interruption may enhance the meiotic stability of the repeat [<a class="bk_pop" href="#sca2.REF.choudhry.2001.2437">Choudhry et al 2001</a>]. Conversely, the lack of CAA interruption in some expanded alleles may increase the instability of the expansion and therefore increase the risk of transmission of a larger expansion to offspring, who may become symptomatic.</p><div id="sca2.T.atxn2_variants_discussed_in_this" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>ATXN2</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1275/table/sca2.T.atxn2_variants_discussed_in_this/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca2.T.atxn2_variants_discussed_in_this_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sca2.T.atxn2_variants_discussed_in_this_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_sca2.T.atxn2_variants_discussed_in_this_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_sca2.T.atxn2_variants_discussed_in_this_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_sca2.T.atxn2_variants_discussed_in_this_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_sca2.T.atxn2_variants_discussed_in_this_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_sca2.T.atxn2_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.496_498CAG(&#x02264;31)<br />(&#x02264;31 CAG repeats)</td><td headers="hd_h_sca2.T.atxn2_variants_discussed_in_this_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln166(&#x02264;31)</td><td headers="hd_h_sca2.T.atxn2_variants_discussed_in_this_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_002973.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002973<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_002964.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002964<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_sca2.T.atxn2_variants_discussed_in_this_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_sca2.T.atxn2_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.496_498CAG(&#x02265;33)<br />(&#x02265;33 CAG repeats)</td><td headers="hd_h_sca2.T.atxn2_variants_discussed_in_this_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln166(&#x02265;33)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The <i>ATXN2</i> protein product, designated ataxin-2, is typically 1,312 amino acids (with a tract of 22 glutamines) or predicted 1,313 amino acids (with a tract of 23 glutamines) [<a class="bk_pop" href="#sca2.REF.imbert.1996.285">Imbert et al 1996</a>, <a class="bk_pop" href="#sca2.REF.pulst.1996.269">Pulst et al 1996</a>, <a class="bk_pop" href="#sca2.REF.sanpei.1996.277">Sanpei et al 1996</a>].</p><p>In brains from both unaffected individuals and individuals with SCA2, ataxin-2 has a cytoplasmic localization. It associates with Golgi membranes [<a class="bk_pop" href="#sca2.REF.huynh.2003.1485">Huynh et al 2003</a>]. Using antibodies to ataxin-2, the expression pattern of ataxin-2 was identical in brains of unaffected individuals and those <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with SCA2 [<a class="bk_pop" href="#sca2.REF.huynh.2000.44">Huynh et al 2000</a>].</p><p>Ataxin-2 interacts with a number of proteins (reviewed in <a class="bk_pop" href="#sca2.REF.scoles.2018.175">Scoles &#x00026; Pulst [2018]</a>), including an ataxin-2 binding protein designated as RNA-binding protein fox-1 homolog 1 (<a href="https://www.ncbi.nlm.nih.gov/protein/NP_001135805.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001135805.1</a>; encoded by <i>RBFOX1</i> (<a href="/nuccore/215272409" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001142333.1</a>), which contains RNA-recognition motifs [<a class="bk_pop" href="#sca2.REF.figueroa.2003.669">Figueroa &#x00026; Pulst 2003</a>]. Interaction of these two proteins suggests a role for ataxin-2 in <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> translation or transport [<a class="bk_pop" href="#sca2.REF.shibata.2000.1303">Shibata et al 2000</a>]. Ataxin-2-deficient mice do not develop marked neurodegeneration but show obesity, reduced fertility, and changes in hippocampal plasticity [<a class="bk_pop" href="#sca2.REF.kiehl.2006.17">Kiehl et al 2006</a>, <a class="bk_pop" href="#sca2.REF.huynh.2009.e6235">Huynh et al 2009</a>]. Subsequent studies have shown additional ataxin-2 interactions most notably with RNA-binding and stress granule proteins including TDP-43 [<a class="bk_pop" href="#sca2.REF.becker.2017.367">Becker et al 2017</a>, <a class="bk_pop" href="#sca2.REF.paul.2018.3648">Paul et al 2018</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic alleles of <i>ATXN2</i> encode a protein that has an abnormally long stretch of glutamine amino acid residues. The biologic consequence of this abnormal protein is undetermined. Studies of cultured cells, human brains, and transgenic mouse lines showed accumulation of ataxin-2 in the cytoplasm without evidence of intranuclear aggregates <a class="bk_pop" href="#sca2.REF.huynh.2000.44">Huynh et al [2000]</a>. In vitro expression of an abnormally expanded ataxin-2 caused apoptotic cell death [<a class="bk_pop" href="#sca2.REF.huynh.2003.1485">Huynh et al 2003</a>]. In the <i>Atxn2</i> transgenic mouse, ataxin-2 interacted with the inositol-triphosphate receptor type 1, causing abnormally increased Ca<sup>++</sup> release from intracellular calcium stores that was ameliorated by feeding mice dantrolene prior to onset of symptoms [<a class="bk_pop" href="#sca2.REF.liu.2009.9148">Liu et al 2009</a>].</p></div><div id="sca2.References"><h2 id="_sca2_References_">References</h2><div id="sca2.Published_Guidelines__Consensus_Sta"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="sca2.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 8-30-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF2">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 8-30-19.</div></li></ul></div><div id="sca2.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.abele.2002.961">Abele M, Burk K, Schols L, Schwartz S, Besenthal I, Dichgans J, Zuhlke C, Riess O, Klockgether T. The aetiology of sporadic adult-onset ataxia. <span><span class="ref-journal">Brain. </span>2002;<span class="ref-vol">125</span>:961–8.</span> [<a href="/pubmed/11960886" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11960886</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.adams.1997.1163">Adams C, Starkman S, Pulst SM. Clinical and molecular analysis of a pedigree of southern Italian ancestry with spinocerebellar ataxia type 2. <span><span class="ref-journal">Neurology. </span>1997;<span class="ref-vol">49</span>:1163–6.</span> [<a href="/pubmed/9339711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9339711</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.almaguermederos.2018.346">Almaguer-Mederos LE, Mesa JML, Gonz&#x000e1;lez-Zald&#x000ed;var Y, Almaguer-Gotay D, Cuello-Almarales D, Aguilera-Rodr&#x000ed;guez R, Falc&#x000f3;n NS, Gispert S, Auburger G, Vel&#x000e1;zquez-P&#x000e9;rez L. Factors associated with ATXN2 CAG/CAA repeat intergenerational instability in Spinocerebellar ataxia type 2. <span><span class="ref-journal">Clin Genet. </span>2018;<span class="ref-vol">94</span>:346–350.</span> [<a href="/pubmed/29756284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29756284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.armstrong.2005.247">Armstrong J, Bonaventura I, Rojo A, Gonzalez G, Corral J, Nadal N, Volpini V, Ferrer I. Spinocerebellar ataxia type 2 (SCA2) with white matter involvement. <span><span class="ref-journal">Neurosci Lett. </span>2005;<span class="ref-vol">381</span>:247–51.</span> [<a href="/pubmed/15896478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15896478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.babovicvuksanovic.1998.383">Babovic-Vuksanovic D, Snow K, Patterson MC, Michels VV. Spinocerebellar ataxia type 2 (SCA 2) in an infant with extreme CAG repeat expansion. <span><span class="ref-journal">Am J Med Genet. </span>1998;<span class="ref-vol">79</span>:383–7.</span> [<a href="/pubmed/9779806" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9779806</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.becker.2017.367">Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, Pulst SM, Taylor JP, Rigo F, Gitler AD. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. <span><span class="ref-journal">Nature. </span>2017;<span class="ref-vol">544</span>:367–71.</span> [<a href="/pmc/articles/PMC5642042/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5642042</span></a>] [<a href="/pubmed/28405022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28405022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.cancel.1997.709">Cancel G, Durr A, Didierjean O, Imbert G, Burk K, Lezin A, Belal S, Benomar A, Abada-Bendib M, Vial C, Guimaraes J, Chneiweiss H, Stevanin G, Yvert G, Abbas N, Saudou F, Lebre AS, Yahyaoui M, Hentati F, Vernant JC, Klockgether T, Mandel JL, Agid Y, Brice A. Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. <span><span class="ref-journal">Hum Mol Genet. </span>1997;<span class="ref-vol">6</span>:709–15.</span> [<a href="/pubmed/9158145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9158145</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.charles.2007.1970">Charles P, Camuzat A, Benammar N, Sellal F, Dest&#x000e9;e A, Bonnet AM, Lesage S, Le Ber I, Stevanin G, D&#x000fc;rr A, Brice A, et al.  Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? <span><span class="ref-journal">Neurology. </span>2007;<span class="ref-vol">69</span>:1970–5.</span> [<a href="/pubmed/17568014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17568014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.choudhry.2001.2437">Choudhry S, Mukerji M, Srivastava AK, Jain S, Brahmachari SK. CAG repeat instability at SCA2 locus: anchoring CAA interruptions and linked single nucleotide polymorphisms. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:2437–46.</span> [<a href="/pubmed/11689490" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11689490</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.costanziporrini.2000.491">Costanzi-Porrini S, Tessarolo D, Abbruzzese C, Liguori M, Ashizawa T, Giacanelli M. An interrupted 34-CAG repeat SCA-2 allele in patients with sporadic spinocerebellar ataxia. <span><span class="ref-journal">Neurology. </span>2000;<span class="ref-vol">54</span>:491–3.</span> [<a href="/pubmed/10668721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10668721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.engel.2004.778">Engel KC, Anderson JH, Gomez CM, Soechting JF. Deficits in ocular and manual tracking due to episodic ataxia type 2. <span><span class="ref-journal">Mov Disord. </span>2004;<span class="ref-vol">19</span>:778–87.</span> [<a href="/pubmed/15254935" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15254935</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.figueroa.2017.e155">Figueroa KP, Coon H, Santos N, Velazquez L, Mederos LA, Pulst SM. Genetic analysis of age at onset variation in spinocerebellar ataxia type 2. <span><span class="ref-journal">Neurol Genet. </span>2017;<span class="ref-vol">3</span>:e155.</span> [<a href="/pmc/articles/PMC5432368/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5432368</span></a>] [<a href="/pubmed/28534046" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28534046</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.figueroa.2003.669">Figueroa KP, Pulst SM. Identification and expression of the gene for human ataxin-2-related protein on chromosome 16. <span><span class="ref-journal">Exp Neurol. </span>2003;<span class="ref-vol">184</span>:669–78.</span> [<a href="/pubmed/14769358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14769358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.filla.1995.793">Filla A, De Michele G, Banfi S, Santoro L, Perretti A, Cavalcanti F, Pianese L, Castaldo I, Barbieri F, Campanella G, Cocozza S. Has spinocerebellar ataxia type 2 a distinct phenotype? Genetic and clinical study of an Italian family. <span><span class="ref-journal">Neurology. </span>1995;<span class="ref-vol">45</span>:793–6.</span> [<a href="/pubmed/7723972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7723972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.freund.2007.732">Freund HJ, Barnikol UB, Nolte D, Treuer H, Auburger G, Tass PA, Samii M, Sturm V. Subthalamic-thalamic DBS in a case with spinocerebellar ataxia type 2 and severe tremor-A unusual clinical benefit. <span><span class="ref-journal">Mov Disord. </span>2007;<span class="ref-vol">22</span>:732–5.</span> [<a href="/pubmed/17265523" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17265523</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.furtado.2002.1625">Furtado S, Farrer M, Tsuboi Y, Klimek ML, de la Fuente-Fernandez R, Hussey J, Lockhart P, Calne DB, Suchowersky O, Stoessl AJ, Wszolek ZK. SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">59</span>:1625–7.</span> [<a href="/pubmed/12451209" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12451209</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.geschwind.1997b.842">Geschwind DH, Perlman S, Figueroa CP, Treiman LJ, Pulst SM. The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. <span><span class="ref-journal">Am J Hum Genet. </span>1997b;<span class="ref-vol">60</span>:842–50.</span> [<a href="/pmc/articles/PMC1712476/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1712476</span></a>] [<a href="/pubmed/9106530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9106530</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.geschwind.1997a.1247">Geschwind DH, Perlman S, Figueroa KP, Karrim J, Baloh RW, Pulst SM. Spinocerebellar ataxia type 6. Frequency of the mutation and genotype- phenotype correlations. <span><span class="ref-journal">Neurology. </span>1997a;<span class="ref-vol">49</span>:1247–51.</span> [<a href="/pubmed/9371902" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9371902</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.huynh.2000.44">Huynh DP, Figueroa K, Hoang N, Pulst SM. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. <span><span class="ref-journal">Nat Genet. </span>2000;<span class="ref-vol">26</span>:44–50.</span> [<a href="/pubmed/10973246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10973246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.huynh.2009.e6235">Huynh DP, Maalouf M, Silva AJ, Schweizer FE, Pulst SM. Dissociated fear and spatial learning in mice with deficiency of ataxin-2. <span><span class="ref-journal">PLoS One. </span>2009;<span class="ref-vol">4</span>:e6235.</span> [<a href="/pmc/articles/PMC2707006/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2707006</span></a>] [<a href="/pubmed/19617910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19617910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.huynh.2003.1485">Huynh DP, Yang HT, Vakharia H, Nguyen D, Pulst SM. Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. <span><span class="ref-journal">Hum Mol Genet. </span>2003;<span class="ref-vol">12</span>:1485–96.</span> [<a href="/pubmed/12812977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12812977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.imbert.1996.285">Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, Weber C, Mandel JL, Cancel G, Abbas N, Durr A, Didierjean O, Stevanin G, Agid Y, Brice A. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. <span><span class="ref-journal">Nat Genet. </span>1996;<span class="ref-vol">14</span>:285–91.</span> [<a href="/pubmed/8896557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8896557</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.kiehl.2006.17">Kiehl TR, Nechiporuk A, Figueroa KP, Keating MT, Huynh DP, Pulst SM. Generation and characterization of Sca2 (ataxin-2) knockout mice. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2006;<span class="ref-vol">339</span>:17–24.</span> [<a href="/pubmed/16293225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16293225</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.lee.2003.858">Lee WY, Jin DK, Oh MR, Lee JE, Song SM, Lee EA, Kim GM, Chung JS, Lee KH. Frequency analysis and clinical characterization of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Korean patients. <span><span class="ref-journal">Arch Neurol. </span>2003;<span class="ref-vol">60</span>:858–63.</span> [<a href="/pubmed/12810491" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12810491</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.liu.2009.9148">Liu J, Tang TS, Tu H, Nelson O, Herndon E, Huynh DP, Pulst SM, Bezprozvanny I. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. <span><span class="ref-journal">J Neurosci. </span>2009;<span class="ref-vol">29</span>:9148–62.</span> [<a href="/pmc/articles/PMC2749883/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2749883</span></a>] [<a href="/pubmed/19625506" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19625506</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.lorenzetti.1997.1009">Lorenzetti D, Bohlega S, Zoghbi HY. The expansion of the CAG repeat in ataxin-2 is a frequent cause of autosomal dominant spinocerebellar ataxia. <span><span class="ref-journal">Neurology. </span>1997;<span class="ref-vol">49</span>:1009–13.</span> [<a href="/pubmed/9339681" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9339681</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.luo.2017.615">Luo L, Wang J, Lo RY, Figueroa KP, Pulst SM, Kuo PH, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH. The initial symptom and motor progression in spinocerebellar ataxias. <span><span class="ref-journal">Cerebellum. </span>2017;<span class="ref-vol">16</span>:615–622.</span> [<a href="/pmc/articles/PMC5429172/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5429172</span></a>] [<a href="/pubmed/27848087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27848087</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.mao.2002.338">Mao R, Aylsworth AS, Potter N, Wilson WG, Breningstall G, Wick MJ, Babovic-Vuksanovic D, Nance M, Patterson MC, Gomez CM, Snow K. Childhood-onset ataxia: testing for large CAG-repeats in SCA2 and SCA7. <span><span class="ref-journal">Am J Med Genet. </span>2002;<span class="ref-vol">110</span>:338–45.</span> [<a href="/pubmed/12116207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12116207</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.moretti.2004.392">Moretti P, Blazo M, Garcia L, Armstrong D, Lewis RA, Roa B, Scaglia F. Spinocerebellar ataxia type 2 (SCA2) presenting with ophthalmoplegia and developmental delay in infancy. <span><span class="ref-journal">Am J Med Genet A. </span>2004;<span class="ref-vol">124A</span>:392–6.</span> [<a href="/pubmed/14735588" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14735588</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.moseley.1998.1666">Moseley ML, Benzow KA, Schut LJ, Bird TD, Gomez CM, Barkhaus PE, Blindauer KA, Labuda M, Pandolfo M, Koob MD, Ranum LP. Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. <span><span class="ref-journal">Neurology. </span>1998;<span class="ref-vol">51</span>:1666–71.</span> [<a href="/pubmed/9855520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9855520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.neuenschwander.2014.1529">Neuenschwander AG, Thai KK, Figueroa KP, Pulst SM. Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis. <span><span class="ref-journal">JAMA Neurol. </span>2014;<span class="ref-vol">71</span>:1529–34.</span> [<a href="/pmc/articles/PMC4939089/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4939089</span></a>] [<a href="/pubmed/25285812" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25285812</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.paul.2018.3648">Paul S, Dansithong W, Figueroa KP, Scoles DR, Pulst SM. Staufen1 links RNA stress granules and autophagy in model of neurodegeneration. <span><span class="ref-journal">Nat Commun. </span>2018;<span class="ref-vol">9</span>:3648.</span> [<a href="/pmc/articles/PMC6128856/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6128856</span></a>] [<a href="/pubmed/30194296" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30194296</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.orozco_diaz.1990.1369">Orozco Diaz G, Nodarse Fleites A, Cordov&#x000e9;s Sagaz R, Auburger G. Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holgu&#x000ed;n, Cuba. <span><span class="ref-journal">Neurology. </span>1990;<span class="ref-vol">40</span>:1369–75.</span> [<a href="/pubmed/2392220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2392220</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.orozco.1989.37">Orozco G, Estrada R, Perry TL, Arana J, Fernandez R, Gonzalez-Quevedo A, Galarraga J, Hansen S. Dominantly inherited olivopontocerebellar atrophy from eastern Cuba. Clinical, neuropathological, and biochemical findings. <span><span class="ref-journal">J Neurol Sci. </span>1989;<span class="ref-vol">93</span>:37–50.</span> [<a href="/pubmed/2809629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2809629</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.payami.2003.425">Payami H, Nutt J, Gancher S, Bird T, McNeal MG, Seltzer WK, Hussey J, Lockhart P, Gwinn-Hardy K, Singleton AA, Singleton AB, Hardy J, Farrer M. SCA2 may present as levodopa-responsive parkinsonism. <span><span class="ref-journal">Mov Disord. </span>2003;<span class="ref-vol">18</span>:425–9.</span> [<a href="/pubmed/12671950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12671950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.pirker.2003.222">Pirker W, Back C, Gerschlager W, Laccone F, Alesch F. Chronic thalamic stimulation in a patient with spinocerebellar ataxia type 2. <span><span class="ref-journal">Mov Disord. </span>2003;<span class="ref-vol">18</span>:222–5.</span> [<a href="/pubmed/12539221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12539221</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.pulst.1996.269">Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, Pearlman S, Starkman S, Orozco-Diaz G, Lunkes A, DeJong P, Rouleau GA, Auburger G, Korenberg JR, Figueroa C, Sahba S. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. <span><span class="ref-journal">Nat Genet. </span>1996;<span class="ref-vol">14</span>:269–76.</span> [<a href="/pubmed/8896555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8896555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.pulst.2005.2297">Pulst SM, Santos N, Wang D, Yang H, Huynh D, Velazquez L, Figueroa KP. Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1A calcium channel modifies age of onset. <span><span class="ref-journal">Brain. </span>2005;<span class="ref-vol">128</span>:2297–303.</span> [<a href="/pubmed/16000334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16000334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.riess.1997.59">Riess O, Laccone FA, Gispert S, Schols L, Zuhlke C, Vieira-Saecker AM, Herlt S, Wessel K, Epplen JT, Weber BH, Kreuz F, Chahrokh-Zadeh S, Meindl A, Lunkes A, Aguiar J, Macek M Jr, Krebsova A, Macek M Sr, Burk K, Tinschert S, Schreyer I, Pulst SM, Auburger G. SCA2 trinucleotide expansion in German SCA patients. <span><span class="ref-journal">Neurogenetics. </span>1997;<span class="ref-vol">1</span>:59–64.</span> [<a href="/pubmed/10735276" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10735276</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.r_b.2004.1258">R&#x000fc;b U, B&#x000fc;rk K, Sch&#x000f6;ls L, Brunt ER, de Vos RA, Diaz GO, Gierga K, Ghebremedhin E, Schultz C, Del Turco D, Mittelbronn M, Auburger G, Deller T, Braak H. Damage to the reticulotegmental nucleus of the pons in spinocerebellar ataxia type 1, 2, and 3. <span><span class="ref-journal">Neurology. </span>2004;<span class="ref-vol">63</span>:1258–63.</span> [<a href="/pubmed/15477548" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15477548</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.r_b.2005.127">R&#x000fc;b U, Del Turco D, Burk K, Diaz GO, Auburger G, Mittelbronn M, Gierga K, Ghebremedhin E, Schultz C, Schols L, Bohl J, Braak H, Deller T. Extended pathoanatomical studies point to a consistent affection of the thalamus in spinocerebellar ataxia type 2. <span><span class="ref-journal">Neuropathol Appl Neurobiol. </span>2005;<span class="ref-vol">31</span>:127–40.</span> [<a href="/pubmed/15771706" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15771706</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.r_b.2003.2257">R&#x000fc;b U, Del Turco D, Del Tredici K, de Vos RA, Brunt ER, Reifenberger G, Seifried C, Schultz C, Auburger G, Braak H. Thalamic involvement in a spinocerebellar ataxia type 2 (SCA2) and a spinocerebellar ataxia type 3 (SCA3) patient, and its clinical relevance. <span><span class="ref-journal">Brain. </span>2003;<span class="ref-vol">126</span>:2257–72.</span> [<a href="/pubmed/12847080" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12847080</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.sanpei.1996.277">Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, Sasaki H, Wakisaka A, Tashiro K, Ishida Y, Ikeuchi T, Koide R, Saito M, Sato A, Tanaka T, Hanyu S, Takiyama Y, Nishizawa M, Shimizu N, Nomura Y, Segawa M, Iwabuchi K, Eguchi I, Tanaka H, Takahashi H, Tsuji S. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. <span><span class="ref-journal">Nat Genet. </span>1996;<span class="ref-vol">14</span>:277–84.</span> [see comments] [<a href="/pubmed/8896556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8896556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.sch_ls.1997a.924">Sch&#x000f6;ls L, Amoiridis G, Buttner T, Przuntek H, Epplen JT, Riess O. Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? <span><span class="ref-journal">Ann Neurol. </span>1997a;<span class="ref-vol">42</span>:924–32.</span> [<a href="/pubmed/9403486" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9403486</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.sch_ls.1997b.1073">Sch&#x000f6;ls L, Gispert S, Vorgerd M, Menezes Vieira-Saecker AM, Blanke P, Auburger G, Amoiridis G, Meves S, Epplen JT, Przuntek H, Pulst SM, Riess O. Spinocerebellar ataxia type 2. Genotype and phenotype in German kindreds. <span><span class="ref-journal">Arch Neurol. </span>1997b;<span class="ref-vol">54</span>:1073–80.</span> [<a href="/pubmed/9311350" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9311350</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.scoles.2018.175">Scoles DR, Pulst SM. Spinocerebellar Ataxia Type 2. <span><span class="ref-journal">Adv Exp Med Biol. </span>2018;<span class="ref-vol">1049</span>:175–95.</span> [<a href="/pubmed/29427103" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29427103</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.seidel.2017.345">Seidel K, Siswanto S, Fredrich M, Bouzrou M, denDunnen WFA, Ozerden I, Korf HW, Melegh B, de Vries JJ, Brunt ER, Auburger G, R&#x000fc;b U. On the distribution of intranuclear and cytoplasmic aggregates in the brainstem of patients with spinocerebellar ataxia type 2 and 3. <span><span class="ref-journal">Brain Pathol. </span>2017;<span class="ref-vol">27</span>:345–55.</span> [<a href="/pubmed/27377427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27377427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.shibata.2000.1303">Shibata H, Huynh DP, Pulst SM. A novel protein with RNA-binding motifs interacts with ataxin-2. <span><span class="ref-journal">Hum Mol Genet. </span>2000;<span class="ref-vol">9</span>:1303–13.</span> [<a href="/pubmed/10814712" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10814712</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.tojima.2018.e283">Tojima M, Murakami G, Hikawa R, Yamakado H, Yamashita H, Takahashi R, Matsui M. Homozygous 31 trinucleotide repeats in the SCA2 Allele are pathogenic for cerebellar ataxia. <span><span class="ref-journal">Neurol Genet. </span>2018;<span class="ref-vol">4</span>:e283.</span> [<a href="/pmc/articles/PMC6244019/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6244019</span></a>] [<a href="/pubmed/30533529" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30533529</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.vel_zquezp_rez.2004.444">Vel&#x000e1;zquez-P&#x000e9;rez L, Seifried C, Santos-Falc&#x000f3;n N, Abele M, Ziemann U, Almaguer LE, Mart&#x000ed;nez-G&#x000f3;ngora E, S&#x000e1;nchez-Cruz G, Canales N, P&#x000e9;rez-Gonz&#x000e1;lez R, Vel&#x000e1;zquez-Manresa M, Viebahn B, von Stuckrad-Barre S, Fetter M, Klockgether T, Auburger G. Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">56</span>:444–7.</span> [<a href="/pubmed/15349876" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15349876</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca2.REF.zesiewicz.2018.464">Zesiewicz TA, Wilmot G, Kuo SH, Perlman S, Greenstein PE, Ying SH, Ashizawa T, Subramony SH, Schmahmann JD, Figueroa KP, Mizusawa H, Schols L, Shaw JD, Dubinsky RM, Armstrong MJ, Gronseth GS, Sullivan KL. Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <span><span class="ref-journal">Neurology. </span>2018;<span class="ref-vol">90</span>:464–71.</span> [<a href="/pmc/articles/PMC5863491/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5863491</span></a>] [<a href="/pubmed/29440566" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29440566</span></a>]</div></li></ul></div></div><div id="sca2.Chapter_Notes"><h2 id="_sca2_Chapter_Notes_">Chapter Notes</h2><div id="sca2.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>14 February 2019 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>12 November 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 August 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 October 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 January 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>31 October 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 January 2001 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 October 1998 (pb) Review posted live</div></li><li class="half_rhythm"><div>2 March 1998 (smp) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1275</span><span class="label">PMID: <a href="/pubmed/20301452" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301452</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sca1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sca3/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1275&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1275/?report=reader">PubReader</a></li><li><a href="/books/NBK1275/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1275" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1275" style="display:none" title="Cite this Page"><div class="bk_tt">Pulst SM. Spinocerebellar Ataxia Type 2. 1998 Oct 23 [Updated 2019 Feb 14]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1275/pdf/Bookshelf_NBK1275.pdf">PDF version of this page</a> (452K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#sca2.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#sca2.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#sca2.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#sca2.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#sca2.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#sca2.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#sca2.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#sca2.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#sca2.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#sca2.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#sca2.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6311[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ATXN2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1275+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1492160" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1492160" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1492160" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1492160" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301363" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Opal P, Ashizawa T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301445" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 8</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 8<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ayhan F, Ikeda Y, Dalton JC, Day JW, Ranum LPW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301375" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 3</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 3<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Paulson H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301433" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 7</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 7<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Garden G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301573" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 14</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 14<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chen DH, Bird TD, Raskind WH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301452" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301452" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04194875f66d18aa93c596">Spinocerebellar Ataxia Type 2 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Spinocerebellar Ataxia Type 2 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:22:00-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE89ABD2E04034F1000000000AA60487&amp;ncbi_session=CE89ABD2E0419481_2726SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1275%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1275&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1275/&amp;ncbi_pagename=Spinocerebellar Ataxia Type 2 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89ABD2E0419481_2726SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>